Verisante Technology, Inc. announced that it has entered into a collaboration with the BC Cancer Agency and Imperial College Healthcare NHS Trust to develop a new application for the company's exclusively licensed platform technology. Imperial College Healthcare NHS Trust will be using Verisante's laser Raman system in a study to determine if the system is able to assist in ascertaining the margins between tumour and normal brain tissue. Verisante is providing Imperial College Healthcare NHS Trust with a Raman system.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0023 USD | -.--% | -.--% | +22,900.00% |
1st Jan change | Capi. | |
---|---|---|
+22,900.00% | 101K | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- VRSEF Stock
- News Verisante Technology Inc.
- Verisante Technology, Inc. Enters into Collaboration with BC Cancer Agency and Imperial College Healthcare NHS Trust to Develop New Application for its Exclusively Licensed Platform Technology